BEIJING, Oct. 14, 2024 (GLOBE NEWSWIRE) — On the morning of October 11, 2024, the 2024 World AgriFood Innovation Conference (WAFI 2024) was grandly opened at the Jinhai Lake International Convention and Exhibition Center in Pinggu district, Beijing. Nearly 800 distinguished guests from 76 countries and regions, including renowned scientists, university presidents, educators, entrepreneurs, and […]
In honor of Hispanic Heritage Month, Weintraub Tobin celebrates diversity in the Firm’s leadership, workforce, community, and client base. https://mma.prnewswire.com/media/2529156/WT_Hispanic_Heritage_in_Leadership___PR_Newswire_2024.jpg “Weintraub is proud to serve some of the most diverse regions in California, and it is important to us that our Firm reflect our communities,” said Managing Shareholder Gary Bradus. “Our diversity of experiences and
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony’s narcolepsy
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Elastic N.V. ("Elastic N.V.") (NYSE:ESTC) concerning possible violations of federal securities laws. Elastic announced on August 30, 2024, that it was reducing its revenue forecast for the year, a move that prompted a
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion, Inc.") (NASDAQ:BMEA) concerning possible violations of federal securities laws. Biomea issued a press release on June 6, 2024, announcing that it "has received notice from the U.S. Food
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Temenos AG ("Temenos AG") (OTC PINK:TMSNY) concerning possible violations of federal securities laws. On February 15, 2024, securities analyst Hindenburg Research published a research report titled Temenos: Major Accounting Irregularities, Failed Products and
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of JFrog Ltd. ("JFrog") (NASDAQ:FROG) concerning possible violations of federal securities laws. JFrog reported financial results on August 7, 2024, for its second quarter ended June 30, 2024, and lowered its guidance for fiscal
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Proto Labs, Inc. ("Proto Labs") (NYSE:PRLB) concerning possible violations of federal securities laws. On November 4, 2022, Proto reported Q3 results meeting the low end of its prior guidance and then announced lower